Back to Press Releases

Revance Launches the Teoxane RHA® Collection with Mepivacaine

The innovative filler line challenges the status quo by replacing the local anesthetic with mepivacaine.

rha-mepi.png

Nashville, TN – August 27, 2025 – Revance, a fast-growing global aesthetics and skincare company, announces the latest innovation in its aesthetic portfolio with the launch of the Teoxane RHA® Collection with Mepivacaine.1 As of today, mepivacaine will replace lidocaine as the anesthetic in the Teoxane RHA® Collection in the U.S. market, celebrating the first major anesthetic innovation in hyaluronic acid filler in almost two decades.2

The Teoxane RHA® Collection with Mepivacaine received FDA approval in 2023 and is exclusively patented by Teoxane for use in dermal fillers.1,3-7 This deliberate, research-driven innovation delivers patient comfort with patient care in mind. 8-9 While new to the aesthetic market, mepivacaine has been widely used in therapeutic areas for over 60 years.10 Mepivacaine features the same mechanism of action as lidocaine, with less local vasodilation, reducing the potential for injection site reactions such as bruising.9-11 Preclinical and clinical studies comparing RHA Redensity® with Mepivacaine to RHA Redensity® with lidocaine, as well as RHA® 4 with Mepivacaine to RHA® 4 with lidocaine found similar rheology, effective pain control, established safety profile, and no change in aesthetic outcomes.1,8,12

“The development of the Teoxane RHA® Collection with Mepivacaine exemplifies Teoxane’s commitment to innovation,” states Valérie Taupin, Founder and CEO of Teoxane. “Mepivacaine represents the first major advancement in pain management in fillers in nearly two decades. It provides an anesthetic effect comparable to currently available products, but with reduced local vasodilation, as demonstrated in the recent article published in RSC Pharmaceutics, 2025, which may result in less bruising. We are proud to bring this patented innovation to providers and offer great patient comfort. Teoxane is leading the way in a next-generation approach to optimal patient experience in aesthetics.

“It’s incredibly rewarding to help bring the next evolution of RHA® to the U.S. market. The addition of mepivacaine reflects our commitment to advancing the patient experience without compromising the outcomes providers have come to expect from the RHA® Collection by Teoxane. We’re proud to lead the way in innovation that matters to both patients and practices,” states Jeff Bedard, Founder and CEO, Revance.

Learn more at rha.revanceaesthetics.com.

About Revance:
Revance is a fast-growing, highly acquisitive, global aesthetics and skincare company committed to delivering innovative aesthetics and market-leading skincare solutions across every stage of life. With a differentiated portfolio and market position, Revance meets the evolving needs of patients and consumers worldwide through continued innovation and the commercialization of new products and treatments. Focused on skin science for life, Revance continues to expand its global footprint, with distribution spanning 60 countries and a significant opportunity to enter new markets.

Revance’s balanced portfolio includes innovative products in the aesthetics space such as DAXXIFY® (daxibotulinumtoxinA-lanm) for injection, the Teoxane RHA® Collection, and SkinPen®, an industry-leading microneedling device. RHA® technology is proprietary to and manufactured in Switzerland by Teoxane SA, and Revance is an independent distributor of Teoxane SA to supply the Teoxane RHA® Collection of dermal fillers to the U.S. market. In addition, its consumer skincare portfolio includes leading brands such as PanOxyl®, Blue Lizard®, StriVectin® and BIOJUVE®.

RHA® is a trademark of TEOXANE SA.

Learn more at Revance.com, RevanceAesthetics.com, CrownLaboratories.com, and CrownAesthetics.com. Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

About Teoxane:
Founded by Valérie Taupin in 2003, Teoxane specializes in developing solutions using hyaluronic acid. With over 20 years of expertise, it is a pioneer in the science of facial beauty. The company was founded on a unique vision: to open the possibilities of aesthetic treatments using high-performance dermal and dermo-cosmetic fillers developed through in-depth scientific research. Through attentive listening, education and establishing the foundations for a safer industry, Teoxane has ushered in a new era in aesthetic medicine. Here, minor beauty procedures wield a significant impact on a patient’s self-image and overall well-being.

www.teoxane.com

Media Contact:
EvolveMKD
Revance@EvolveMKD.com

References:

  1. RHA® Directions for Use. 2025.
  2. Micheels P, Besse S, Elias B, et al. J Clin Cosmet Dermatol 8(1): dx.doi.org/70.16966/2576-2826.180
  3. US11,406,738
  4. US10,413,637
  5. US10,786,601
  6. US10,322,212
  7. US97,892,26
  8. Kaufman-Janette J, Joseph JH, Dayan SH, et al. Dermatol surg. 2022;48(10):1065- 1070.
  9. Faivre J, Brusini R, Jing J et al. RSC Pharmaceutics. 2025,2,814-823
  10. Brockmann WG. Gen Dent. 2014;62(6):70-75.
  11. Catterall WA, Mackie K. Local anesthetics. In: McGraw-Hill, ed. The Pharmacological Basis of Therapeutics. Vol 12th ed. New York, NY: Goodman & Gilman’s 2011:565-582.
  12. Brusini R, Iehl J, Clerc E, et al. Pharmaceutics. 2022.26:14(8):1553

RHA® Collection of Fillers, by Teoxane

⁠The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine and have shown no significant impact on gel properties, including rheology and degradation profile.

Approved Uses
The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4.

RHA Redensity® is for injection into the facial tissue for the correction of moderate to severe dynamic perioral rhytids; and RHA® 2 and RHA® 4 are for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, in adults 22 or older. RHA® 3 is for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds, and also used to augment lip fullness in adults 22 or older.

IMPORTANT SAFETY INFORMATION

Are there any reasons why I should not receive any RHA® injectable gel formulation?
Do not receive if you have a history of multiple severe allergies or severe allergic reactions; if you are allergic to lidocaine or mepivacaine or gram-positive bacterial proteins; or if you have a bleeding disorder.

What precautions should I discuss with my doctor?

  • Tell your doctor if you are pregnant or breastfeeding as the safety of these products for use during pregnancy or while breastfeeding has not been studied
  • Tell your doctor if you have a history of excessive scarring, keloid formations or pigmentation disorders, as use of these products may result in additional scars or changes in pigmentation
  • Tell your doctor if you are planning laser treatments or a chemical peel, as there is a possible risk of inflammation at the treatment site if these procedures are performed after treatment
  • Tell your doctor if you are on immunosuppressive therapy used to decrease your immune response, as use of these products may result in an increased risk of infection
  • Tell your doctor if you are using medications that can prolong bleeding, such as aspirin, ibuprofen, or other blood thinners, as this may increase bruising or bleeding at the injection site
  • The safety and effectiveness of RHA® fillers in areas other than those indicated have not been established in U.S. clinical studies
  • Patients who experience skin injury near the site of injection with this product may be at a higher risk for side effects
  • Minimize strenuous exercise, exposure to extensive sun or heat, and alcoholic beverages within the first 24 hours following treatment

What are possible side effects?
The most commonly reported side effects included injection-site redness, swelling, pain, tenderness, firmness, lumps/bumps, bruising, discoloration, and itching.

One of the risks with using these products is unintentional injection into a blood vessel, and while rare, the complications can be serious and may be permanent. These complications, which have been reported for facial injections, can include vision abnormalities, blindness, stroke, temporary scabs, or permanent scarring.

Delayed-onset inflammation near the site of dermal filler injections is one of the known side effects associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures.

Typically, the reported inflammation was responsive to being treated or resolved on its own.

As with all skin injection procedures, there is a risk of infection and recurrence of herpetic eruptions.

To report a side effect with any RHA® product, please call Revance at (877) 373-8669. Please visit RHACollection.com or talk to your doctor for more information.

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®. All other trademarks are the property of their respective owners.

Available by prescription only.

RHA-00220

DAXXIFY® (daxibotulinumtoxinA-lanm) injection IMPORTANT SAFETY INFORMATION

INDICATION

DAXXIFY® (daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.

WARNING: DISTANT SPREAD OF TOXIN EFFECT
The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.

IMPORTANT SAFETY INFORMATION


Contraindications

DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions

Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency units of DAXXIFY® are not interchangeable with preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions

The most commonly observed adverse reactions are:
Glabellar lines (≥1%): headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).

Drug Interactions

Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations

DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch

DAXI-004726

The long-term efficacy and safety outcomes of RHA® with lidocaine are applicable to RHA® with mepivacaine and have shown no significant impact on gel properties, including rheology and degradation profile.

PLEASE SEE FULL DIRECTIONS FOR USE

RHA® Collection of Fillers, by Teoxane

Indications


The Teoxane RHA® Collection of resilient hyaluronic acid (HA) fillers includes RHA Redensity®, RHA® 2, RHA® 3 and RHA® 4.

RHA Redensity® is indicated for injection into the dermis and superficial dermis of the face, for the correction of moderate to severe dynamic perioral rhytids in adults 22 or older. RHA® 2 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older. RHA® 3 is indicated for injection into the mid-to-deep dermis for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds and is also indicated for injection into the vermillion body, vermillion border and oral commissure to achieve lip augmentation and lip fullness in adults 22 or older. RHA® 4 is indicated for injection in the deep dermis to superficial subcutaneous tissue for the correction of moderate to severe dynamic facial wrinkles and folds, such as nasolabial folds in adults 22 or older.

IMPORTANT SAFETY INFORMATION


Contraindications


Do not use in patients who have severe allergies, marked by a history of anaphylaxis or multiple severe allergies, or in patients with a history of allergies to gram-positive bacterial proteins or local anesthetics of the amide type, such as lidocaine and mepivacaine.

Do not use in patients with bleeding disorders.

Warnings


Do not inject into blood vessels. Introduction of these products into the vasculature may lead to embolization, occlusion of the vessels, ischemia, or infarction. Take extra care when injecting soft-tissue fillers; for example, inject the product slowly and apply the least amount of pressure necessary. Rare, but serious, adverse events associated with the intravascular injection of soft-tissue fillers in the face have been reported and include temporary or permanent vision impairment, blindness, cerebral ischemia or cerebral hemorrhage leading to stroke, skin necrosis, and damage to underlying facial structures.

Immediately stop the injection if a patient exhibits any of the following symptoms: changes in vision, signs of a stroke, blanching of the skin, or unusual pain during or shortly after the procedure. Patients should receive prompt medical attention and, possibly, evaluation by an appropriate healthcare professional specialist should an intravascular injection occur.

Product use at specific sites in which an active inflammatory process or infection is present should be deferred until the underlying process has been controlled.

Precautions


These products should only be used by healthcare professionals who have appropriate training, experience, and knowledge of facial anatomy.

Discuss the potential risks of soft-tissue injections with your patients prior to treatment and ensure that patients are aware of signs and symptoms of potential complications.

The safety and effectiveness for the treatment of anatomic regions other than the labeled indications have not been established in controlled U.S. clinical studies.

As with all transcutaneous procedures, dermal filler implantation carries a risk of infection. Standard precautions associated with injectable materials should be followed.

The safety for use in sites in the presence of other implants, during pregnancy, in breastfeeding females, and in patients with known susceptibility to keloid formation, hypertrophic scarring, and pigmentation disorders has not been studied.

Use with caution in patients on immunosuppressive therapy.

Patients who are using products that can prolong bleeding (such as thrombolytics, anticoagulants, or inhibitors of platelet aggregation) may experience increased bruising or bleeding at treatment sites.

Patients with a history of herpetic eruptions may experience reactivation of the herpes.

There is a possible risk of inflammation at the implant site if laser treatments or a chemical peel are performed after treatment.

Use as supplied. Modification or use of the product outside the Directions for Use may adversely impact the sterility, safety, homogeneity, or performance of the product.

For single patient use. Do not reuse a syringe between two treatments and/or between two patients. Do not resterilize.

Adverse Events


The most commonly reported side effects were firmness, redness, tenderness, swelling, lumps/bumps, bruising, discoloration, pain and itching. Most of these events were mild or moderate and resolved within 14 days.

Delayed-onset inflammation near the site of dermal filler injections is one of the known adverse events associated with dermal fillers. Cases of delayed-onset inflammation have been reported to occur at the dermal filler treatment site following viral or bacterial illnesses or infections, vaccinations, or dental procedures. Typically, the reported inflammation was responsive to treatment or resolved on its own.

To report an adverse reaction with any RHA® product, please call Revance at (877) 373-8669.

RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by Revance®.

Available by Prescription only

RHA-00221.11

SkinPen®

Indications for Use

The SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems are microneedling devices and accessories intended to be used as a treatment to improve the appearance of wrinkles of the neck for Fitzpatrick skin types II - IV and to improve the appearance of facial acne scars in adults with all Fitzpatrick skin types aged 22 years and older. Indications and body treatment areas may vary based on your country.

Contraindications

The use of the SkinPen® Precision Elite, SkinPen® Precision and MicroPen EVO™ systems should not be used on patients who have active skin cancer in the treatment area(s), have open wounds, sores, or irritated skin in the treatment area(s), have an allergy to stainless steel or anesthetics, have a hemorrhagic (bleeding) disorder or hemostatic (bleeding) dysfunction, are pregnant or nursing, are currently taking drugs with the ingredient isotretinoin (such as Accutane®). Note: These products are not intended for transdermal (under the skin) delivery of topical products such as cosmetics, drugs, or biologics. For full safety information, instructions for use manual and clinical trial details, as applicable, visit us at skinpen.com and micropenevo.com.

Instagram LinkedIn

©2025 REVANCE. RHA® and RHA Redensity® are registered trademarks of TEOXANE SA, manufactured in Switzerland. The Teoxane RHA® Collection is exclusively distributed by REVANCE. All other trademarks are the property of their respective owners. CORP-00147

CALIFORNIA PRIVACY POLICYCALIFORNIA COMPLIANCE DECLARATIONPRIVACY POLICYTERMS OF USE
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.